Browse studies
Find your next paid study
3 recruiting studies matching your filters
Phase 1
A Phase 1, First-in-human, Open-label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Oral CDK2 Degrader NKT3964 in Adults With Advanced/Metastatic Solid Tumors
The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determ…
Solid TumorAdvanced Solid TumorSolid Tumor, Adult+25 more
NiKang Therapeutics, Inc.NCT06586957
Phase 2
A Phase II Multi-Center Open-label Randomized Study of CAPecitabine in Combination With ELAcestrant Versus Capecitabine Alone in Advanced Estrogen Receptor-Positive Breast Cancer (CAPELA)
The goal of this research study is to compare a combination of two drugs, capecitabine and elacestrant to capecitabine alone as a treatment for advanced estrog…
Estrogen-receptor-positive Breast CancerMetastatic Breast CancerBreast Cancer+6 more
Kristina A. FanucciNCT07222215
Phase 1
A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of INX-315 in Patients With Advanced Cancer
Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers. This…
Breast CancerBreast Cancer MetastaticHormone Receptor Positive Tumor+6 more
Incyclix BioNCT05735080